Granulocyte-macrophage colony-stimulating factor

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 16, 2022
Professional Services, Health, Finance, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Twitter, GM-CSF, Employment, Degenerative disease, Granulocyte-macrophage colony-stimulating factor, Nasdaq, Pulmonology, Inc., Financial compensation, NASDAQ, Board, Company, APAP, LinkedIn, Pharmaceutical industry, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of an employee inducement award.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of an employee inducement award.
  • On March 14, 2022, the Compensation Committee of Savara's Board of Directors granted the inducement award to a new employee who recently joined the Company.
  • The inducement award consists of options to purchase 40,000 shares of the Company's common stock.
  • This equity award was granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees acceptance of employment with the Company.

Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Retrieved on: 
Wednesday, March 9, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Savara, Degenerative disease, Granulocyte-macrophage colony-stimulating factor, Inc., Pulmonology, GM-CSF, Twitter, Conference, APAP, LinkedIn, Pharmaceutical industry

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimers 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimers 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET.
  • A live webcast of the presentation will be available on Savaras website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
  • Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
  • Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
Granulocyte-macrophage colony-stimulating factor, Time, NASDAQ, Phenotype, AACR, Clinical trial, American Association for Cancer Research, Ernest, Company, Research, Lymphatic system, Chemoradiotherapy, GM-CSF, Securities Exchange Act of 1934, Cancer, Regulation, Neoplasm, American Association, 2021 Essex County Council election, AB, ONC, Oncolytics Biotech, TSX, COVID-19, GBM, Association, Glioblastoma, Poster, Biotechnology, Forward-looking statement, SAN, Travel, Pharmaceutical industry

The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.

Key Points: 
  • The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.
  • Details on the poster and corresponding abstract are shown below.
  • Oncolytics will provide details on the results described in this abstract following publication of the abstract and corresponding poster at the AACR Annual Meeting in April, in accordance with conference embargo policies regarding clinical trials abstracts.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
Granulocyte-macrophage colony-stimulating factor, Time, NASDAQ, Phenotype, AACR, Clinical trial, American Association for Cancer Research, Ernest, Company, Research, Lymphatic system, Chemoradiotherapy, GM-CSF, Securities Exchange Act of 1934, Cancer, Regulation, Neoplasm, American Association, 2021 Essex County Council election, AB, ONC, Oncolytics Biotech, TSX, COVID-19, GBM, Association, Glioblastoma, Poster, Biotechnology, Forward-looking statement, SAN, Travel, Pharmaceutical industry

The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.

Key Points: 
  • The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.
  • Details on the poster and corresponding abstract are shown below.
  • Oncolytics will provide details on the results described in this abstract following publication of the abstract and corresponding poster at the AACR Annual Meeting in April, in accordance with conference embargo policies regarding clinical trials abstracts.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Humanigen to Present and Participate at Multiple Investor Events in March

Retrieved on: 
Friday, February 25, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Nasdaq, Judgement, Forward-looking statement, Patient, GM-CSF, Knowledge, COVID-19, Goal, LinkedIn, Risk, Twitter, Graft-versus-host disease, Granulocyte-macrophage colony-stimulating factor, SEC, Risk management, Facebook

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
  • For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.
  • All statements other than statements of historical facts contained in this press release are forward-looking statements.
  • Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events.

Humanigen to Present at BIO CEO & Investor Conference

Retrieved on: 
Friday, February 11, 2022
Biotechnology, Pharmaceutical, Health, SEC, Forward-looking statement, Knowledge, Patient, Risk, LinkedIn, GM-CSF, Graft-versus-host disease, COVID-19, Twitter, Granulocyte-macrophage colony-stimulating factor, Judgement, Nasdaq, Goal, Risk management, Facebook

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen) is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen) is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
  • For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.
  • All statements other than statements of historical facts contained in this press release are forward-looking statements.
  • Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events.

Humanigen Launches Managed Access Program for Lenzilumab

Retrieved on: 
Thursday, February 10, 2022
Biotechnology, Infectious Diseases, Hospitals, Health, Pharmaceutical, Granulocyte-macrophage colony-stimulating factor, CFO, Forward-looking statement, NHS Counter Fraud and Security Management Service Division, Chemokine, Twitter, Rheumatoid arthritis, GM-CSF, Group, Knowledge, Hospital, Patient, CLIN, Graft-versus-host disease, SEC, AIM, Biotechnology, Goal, Health care, Physician, COO, Nasdaq, LinkedIn, Judgement, Risk, COVID-19, Medicine, Pharmaceutical industry, Facebook, MD, Humanigen, Clinigen, HUMANIGEN, CLINIGEN

We are pleased to be working with Clinigen to provide access to lenzilumab on a patient-by-patient basis in the United Kingdom and certain other European countries, said Timothy E. Morris, COO and CFO of Humanigen.

Key Points: 
  • We are pleased to be working with Clinigen to provide access to lenzilumab on a patient-by-patient basis in the United Kingdom and certain other European countries, said Timothy E. Morris, COO and CFO of Humanigen.
  • We are proud to partner with Humanigen in offering this potential treatment option for certain hospitalized patients with COVID-19 in the UK and across Europe.
  • Clinigen currently oversees more than 161 similar managed access programs for other companies and has access to over 20,000 healthcare providers in 5,000 hospitals across more than 120 countries.
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.

Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France

Retrieved on: 
Wednesday, February 9, 2022
Other Manufacturing, Genetics, Clinical Trials, Manufacturing, Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Granulocyte-macrophage colony-stimulating factor, Pandemic, Forward-looking statement, Lenzilumab, Chemokine, Conditional, Twitter, Rheumatoid arthritis, GM-CSF, Union, AAP, Hérouville-Saint-Clair, NIH, United States security assistance to the Palestinian National Authority, Technology, Knowledge, Patient, Risk, Graft-versus-host disease, CDMO, SEC, Saint Clair, Government of France, Goal, Accelerated approval (FDA), Emergency Use Authorization, Nasdaq, Partnership, LinkedIn, Judgement, AD, Fontenay-sous-Bois, COVID-19, Pharmaceutical industry, Video game, Facebook, Humanigen, Cenexi, HUMANIGEN, CENEXI

Humanigen and Cenexi will enter into discussions to potentially expand the agreement to other services Cenexi offers.

Key Points: 
  • Humanigen and Cenexi will enter into discussions to potentially expand the agreement to other services Cenexi offers.
  • Humanigen plans to include the Cenexi Normandy site in certain of its future regulatory filings for lenzilumab for COVID-19 and other indications.
  • In addition, Cenexi will assist Humanigen as it seeks an advanced purchase agreement for lenzilumab in France.
  • The goal of the collaboration with Cenexi is to further our efforts to establish a supply of lenzilumab made in Europe, commented Cameron Durrant, chief executive officer of Humanigen.

Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

Retrieved on: 
Monday, January 10, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, SHIELD, Knowledge, GM, Degenerative disease, Rating, LinkedIn, Risk, Security (finance), Goal, Patient, Physician, Chemokine, Asthma, Mayo Clinic, GM-CSF, U.S. Securities and Exchange Commission, Chronic myelomonocytic leukemia, NIH, Toxicity, Forward-looking statement, Neurotoxicity, DLBCL, CRS, COVID, Rheumatoid arthritis, CEO, NHL, Company, Nasdaq, Judgement, FDA, COVID-19, Disease, Twitter, Granulocyte-macrophage colony-stimulating factor, Inflammation, Society, Cytokine release syndrome, Toxic shock syndrome, Adoption, Vaccine, Pharmaceutical industry, Risk management, Hematology, Facebook

In agreement with FDA, we will also seek to demonstrate the beneficial impact that lenzilumab may have on healthcare resource utilization.

Key Points: 
  • In agreement with FDA, we will also seek to demonstrate the beneficial impact that lenzilumab may have on healthcare resource utilization.
  • We are very encouraged with the outcome of our meeting with FDA, said Dr. Cameron Durrant, Chairman and CEO of Humanigen.
  • Defining a potential registration pathway across multiple indications is an important next step in our development of lenzilumab.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.

Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved

Retrieved on: 
Wednesday, January 5, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Knowledge, Graft-versus-host disease, COVID-19, The Lancet, Chief executive officer, Infection, Emergency Use Authorization, Patient, Forward-looking statement, GM-CSF, National, Goal, Twitter, Risk, GM, Comment, Survival, CEO, SEC, Chemokine, LinkedIn, CRP, FDA, Population, National Institute of Allergy and Infectious Diseases, National Institute, Rheumatoid arthritis, Judgement, Incidence, EUA, Nasdaq, NIH, Granulocyte-macrophage colony-stimulating factor, Death, Pharmaceutical industry, Lancet, Facebook

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study has been achieved.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study has been achieved.
  • Hospitalized COVID-19 patients enrolled in ACTIV-5/BET-B were randomized to receive either lenzilumab and remdesivir or placebo and remdesivir.
  • The primary endpoint of ACTIV-5/BET-B is the incidence of invasive mechanical ventilation or death through day 29.
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.